Vaxart, INC 8-K filings

Vaxart's oral bivalent norovirus vaccine candidate showed positive results in a Phase 1 trial, demonstrating an antibody rise in lactating mothers and their breast milk.

Vaxart reported its full year 2023 financial results, highlighted by a new CEO appointment and progress in its oral vaccine development programs, including a BARDA contract for a COVID-19 vaccine trial.

Vaxart has appointed Steven Lo as its new Chief Executive Officer, President, and a member of the Board, effective March 18, 2024, succeeding Michael J. Finney, who will remain as Chairman of the Board.

Vaxart, Inc. has established a new stock incentive plan to attract new employees, allocating 3,000,000 shares for this purpose.

Vaxart, Inc. has received notification from Nasdaq that it has regained compliance with the minimum bid price requirement after its stock price closed above $1.00 for ten consecutive business days.

Vaxart has formalized a separation agreement with its former CEO, Andrei Floroiu, outlining the terms of his departure and associated benefits.

Vaxart secures a Nasdaq extension to regain compliance with minimum bid price and a $9.27 million BARDA award to advance its oral COVID-19 vaccine.

Vaxart, a clinical-stage biotechnology company, has entered into a securities purchase agreement with RA Capital Healthcare Fund, L.P. for a $10 million registered direct offering of common stock.

Vaxart has been awarded a $9.3 million contract for clinical trial planning and has appointed an interim CEO following the resignation of Andrei Floroiu.